FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2800516277> ?p ?o ?g. }

• W2800516277 endingPage "e0195823" @default.
• W2800516277 startingPage "e0195823" @default.
• W2800516277 abstract "An increasing number of monoclonal antibodies and derivatives such as antibody-drug conjugates (ADC) are of the IgG1 and IgG4 isotype with distinct structural and functional properties. In cases where antibody-mediated cytotoxicity is not desired, IgG4 is often used, as its Fc region is relatively poor at inducing antibody-dependent cell-mediated or complement-dependent cytotoxicity. IgG4 ADCs with highly cytotoxic drugs against proliferating target cells but which lack or have diminished antibody effector functions against quiescent cells may have a favorable safety profile compared to IgG1. Another unique property of the IgG4 subclass is the capability to exchange half antibodies in vivo creating randomly bispecific antibodies. To investigate the functional properties of process-derived antibody species, and determine the influence of shuffling on the therapeutic efficacy, several model antibodies on the basis of the anti-CD138 antibody-drug conjugate BT062 (Indatuximab ravtansine) were generated: (I) A wild type nBT062, (II) a stable nBT062 comprising mutations to prevent half-antibody exchange, (III) a half nBT062 lacking covalent binding between two heavy chains and (IV) a stabilized, bispecific nBT062-natalizumab antibody with a second, monovalent specificity against CD49d. All nBT062 model variants were capable of CD138-specific binding and antigen-mediated internalization into cells. Furthermore, all nBT062 models inhibited tumor growth in vitro after conjugation with the maytansinoid DM4. The in vivo effects of the different molecular variants were assessed in the MAXF1322 xenograft model. The bispecific nBT062-natalizumab-DM4 demonstrated the least efficacy and was only moderately active even without the co-administration of a human IgG preparation. Wild type, stable and half nBT062-DM4 models demonstrated great anti-tumor activities. The efficacy of wild type and half nBT062-DM4 was reduced in the presence of IgG, while stable nBT062-DM4 was only marginally influenced. These pre-clinical data demonstrate the advantage of introducing half-antibody exchange-preventing mutations into therapeutic IgG4-based antibody drug-conjugates." @default.
• W2800516277 created "2018-05-17" @default.
• W2800516277 creator A5036566664 @default.
• W2800516277 creator A5054524461 @default.
• W2800516277 creator A5056872315 @default.
• W2800516277 creator A5058054846 @default.
• W2800516277 creator A5060962640 @default.
• W2800516277 creator A5068778977 @default.
• W2800516277 creator A5080462595 @default.
• W2800516277 date "2018-04-19" @default.
• W2800516277 modified "2023-09-29" @default.
• W2800516277 title "Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate" @default.
• W2800516277 cites W1483697311 @default.
• W2800516277 cites W1504758596 @default.
• W2800516277 cites W1908675203 @default.
• W2800516277 cites W1966286047 @default.
• W2800516277 cites W1972303144 @default.
• W2800516277 cites W1976554179 @default.
• W2800516277 cites W1982135190 @default.
• W2800516277 cites W1985190512 @default.
• W2800516277 cites W1986864699 @default.
• W2800516277 cites W1991787503 @default.
• W2800516277 cites W2015714938 @default.
• W2800516277 cites W2029750535 @default.
• W2800516277 cites W2031429783 @default.
• W2800516277 cites W2034300749 @default.
• W2800516277 cites W2035154199 @default.
• W2800516277 cites W2038319340 @default.
• W2800516277 cites W2047130177 @default.
• W2800516277 cites W2049362047 @default.
• W2800516277 cites W2049952530 @default.
• W2800516277 cites W2050656150 @default.
• W2800516277 cites W2053872195 @default.
• W2800516277 cites W2055546194 @default.
• W2800516277 cites W2077853765 @default.
• W2800516277 cites W2090542053 @default.
• W2800516277 cites W2094955456 @default.
• W2800516277 cites W2097529056 @default.
• W2800516277 cites W2102408296 @default.
• W2800516277 cites W2104706142 @default.
• W2800516277 cites W2113266466 @default.
• W2800516277 cites W2116547757 @default.
• W2800516277 cites W2131340972 @default.
• W2800516277 cites W2135611522 @default.
• W2800516277 cites W2164143412 @default.
• W2800516277 cites W2169656611 @default.
• W2800516277 cites W2169829977 @default.
• W2800516277 cites W2170371914 @default.
• W2800516277 cites W2323575157 @default.
• W2800516277 cites W2409645736 @default.
• W2800516277 cites W2573866523 @default.
• W2800516277 cites W2597077510 @default.
• W2800516277 cites W4293241248 @default.
• W2800516277 cites W4300765378 @default.
• W2800516277 cites W5193816 @default.
• W2800516277 doi "https://doi.org/10.1371/journal.pone.0195823" @default.
• W2800516277 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5908158" @default.
• W2800516277 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29672587" @default.
• W2800516277 hasPublicationYear "2018" @default.
• W2800516277 type Work @default.
• W2800516277 sameAs 2800516277 @default.
• W2800516277 citedByCount "15" @default.
• W2800516277 countsByYear W28005162772018 @default.
• W2800516277 countsByYear W28005162772020 @default.
• W2800516277 countsByYear W28005162772021 @default.
• W2800516277 countsByYear W28005162772022 @default.
• W2800516277 countsByYear W28005162772023 @default.
• W2800516277 crossrefType "journal-article" @default.
• W2800516277 hasAuthorship W2800516277A5036566664 @default.
• W2800516277 hasAuthorship W2800516277A5054524461 @default.
• W2800516277 hasAuthorship W2800516277A5056872315 @default.
• W2800516277 hasAuthorship W2800516277A5058054846 @default.
• W2800516277 hasAuthorship W2800516277A5060962640 @default.
• W2800516277 hasAuthorship W2800516277A5068778977 @default.
• W2800516277 hasAuthorship W2800516277A5080462595 @default.
• W2800516277 hasBestOaLocation W28005162771 @default.
• W2800516277 hasConcept C109316439 @default.
• W2800516277 hasConcept C134306372 @default.
• W2800516277 hasConcept C147483822 @default.
• W2800516277 hasConcept C150903083 @default.
• W2800516277 hasConcept C153911025 @default.
• W2800516277 hasConcept C159654299 @default.
• W2800516277 hasConcept C179223381 @default.
• W2800516277 hasConcept C185592680 @default.
• W2800516277 hasConcept C197336794 @default.
• W2800516277 hasConcept C202751555 @default.
• W2800516277 hasConcept C203014093 @default.
• W2800516277 hasConcept C207001950 @default.
• W2800516277 hasConcept C2777092746 @default.
• W2800516277 hasConcept C2777325958 @default.
• W2800516277 hasConcept C2777726029 @default.
• W2800516277 hasConcept C33923547 @default.
• W2800516277 hasConcept C40677261 @default.
• W2800516277 hasConcept C502942594 @default.
• W2800516277 hasConcept C542903549 @default.
• W2800516277 hasConcept C55493867 @default.
• W2800516277 hasConcept C86803240 @default.
• W2800516277 hasConceptScore W2800516277C109316439 @default.

• next